Discontinuation of Vyndaqel on Dec. 31, 2025

The Amyloid Research Consortium recently announced that Pfizer will discontinue Vyndaqel® (tafamidis meglumine), on Dec. 31, 2025. This medication is used to treat transthyretin amyloid cardiomyopathy.

Covered alternative

Vyndamax® (tafamidis) is a covered alternative on UnitedHealthcare® Medicare Advantage (Individual and Group) plans, including non-SNPs, D-SNPs and C-SNPs as well as stand-alone Part D prescription drug plans. 

For members with an active prior authorization for Vyndaqel, we don’t require a new authorization to transition to Vyndamax. However, a new prescription for Vyndamax must be sent to the pharmacy to continue treatment.